Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available on-demand starting 7:00 AM EDT on September 12. Werewolf is focused on conditionally activated therapeutics that stimulate the immune system targeting cancer. Their leading candidates, WTX-124 and WTX-330, aim to improve treatment for solid tumors by activating selectively within the tumor microenvironment while remaining inactive elsewhere.
Details
News Market Reaction – HOWL
The recorded move for HOWL in the trading session of this news was +0.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference, taking place in New York, NY from September 12-14, 2022.
Management’s pre-recorded presentation will be made available on-demand at 7:00 AM EDT on September 12. A link to the webcast will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay of the webcast will be available for approximately 90 days.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. To learn more visit www.werewolftx.com.
Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
Josh.Rappaport@sternir.com
Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.